Fulton Bank N.A. Has $5.12 Million Holdings in Amgen Inc. $AMGN

Posted by Francis Steltz on Jul 2nd, 2026

Fulton Bank N.A. cut its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 16.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,566 shares of the medical research company’s stock after selling 2,853 shares during the period. Fulton Bank N.A.’s holdings in Amgen were worth $5,125,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after acquiring an additional 961,975 shares in the last quarter. State Street Corp boosted its position in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the period. Capital World Investors grew its holdings in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after purchasing an additional 4,302,237 shares during the last quarter. Capital International Investors grew its holdings in Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after purchasing an additional 282,219 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: A federal judge blocked Colorado’s first-of-its-kind price cap on Enbrel, easing a potentially important state-level pricing overhang for one of Amgen’s blockbuster drugs. Judge blocks Colorado’s first-of-its-kind price cap on Amgen’s Enbrel
Positive Sentiment: Amgen’s pipeline remains a point of investor interest, with commentary highlighting MariTide and olpasiran as potential growth drivers and a study update on evolocumab reinforcing focus on the PCSK9 franchise. Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran Amgen Refines Its PCSK9 Franchise with New Evolocumab Bioavailability Study
Positive Sentiment: Analyst coverage continues to view Amgen favorably versus peers, citing its broader product mix, deeper pipeline, and steadier growth outlook. Amgen or Biogen: Which Biotech Stock Appears Better Poised?
Neutral Sentiment: Investor attention on AMGN has been elevated, which can reflect anticipation around upcoming catalysts but does not by itself change fundamentals. Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Negative Sentiment: Regulatory pressure remains a key risk, as European regulators have recommended revoking Tavneos’ marketing authorization and a journal retraction further weakens the drug’s case for continued use. Amgen (AMGN) Faces EU Push To Revoke Tavneos Approval Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown

Amgen Trading Down 0.2%

Shares of Amgen stock opened at $361.33 on Thursday. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $391.29. The company’s fifty day simple moving average is $341.28 and its 200-day simple moving average is $347.34. The company has a market cap of $195.01 billion, a price-to-earnings ratio of 25.14, a PEG ratio of 3.56 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the company earned $4.90 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 22.39 EPS for the current year.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent analyst reports. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research report on Thursday, June 18th. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Amgen presently has an average rating of “Hold” and a consensus target price of $355.50.

View Our Latest Research Report on AMGN

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.